Rodrigo E Mendes Selected Research

telavancin

1/2020	Regional analysis of telavancin and comparator antimicrobial activity against multidrug-resistant Staphylococcus aureus collected in the USA 2014-2016.
2/2019	In vitro activity of telavancin against Staphylococcus aureus causing pneumonia or skin and skin structure infections with concomitant bloodstream infections in United States hospitals (2012-2016).
6/2017	Activity of telavancin against Gram-positive pathogens isolated from bone and joint infections in North American, Latin American, European and Asia-Pacific nations.
11/2016	Telavancin activity tested against a collection of Staphylococcus aureus isolates causing pneumonia in hospitalized patients in the United States (2013-2014).
3/2015	Telavancin activity when tested by a revised susceptibility testing method against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide (2011-2013).
1/2015	Baseline activity of telavancin against Gram-positive clinical isolates responsible for documented infections in U.S. hospitals (2011-2012) as determined by the revised susceptibility testing method.
11/2010	Telavancin activity against Gram-positive bacteria isolated from respiratory tract specimens of patients with nosocomial pneumonia.
8/2010	Worldwide summary of telavancin spectrum and potency against Gram-positive pathogens: 2007 to 2008 surveillance results.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Rodrigo E Mendes Research Topics

Disease

65	Infections 07/2022 - 04/2008
11	Pneumonia (Pneumonitis) 06/2021 - 11/2010
6	Sepsis (Septicemia) 01/2022 - 12/2009
6	Urinary Tract Infections (Urinary Tract Infection) 12/2020 - 12/2015
5	Healthcare-Associated Pneumonia 07/2022 - 11/2010
5	Endocarditis 01/2021 - 09/2009
5	Bacteremia 01/2020 - 09/2009
5	Bacterial Pneumonia 12/2018 - 09/2012
4	Ventilator-Associated Pneumonia 07/2022 - 07/2015
3	Intraabdominal Infections 01/2019 - 12/2015
3	Osteomyelitis 04/2018 - 01/2016
2	Soft Tissue Infections 12/2021 - 02/2015
2	Cystic Fibrosis (Mucoviscidosis) 06/2021 - 07/2016
2	Respiratory Tract Infections (Respiratory Tract Infection) 05/2017 - 01/2016
1	Communicable Diseases (Infectious Diseases) 01/2020
1	Bacterial Endocarditis 01/2019
1	Pyelonephritis 08/2018
1	Neoplasms (Cancer) 01/2018
1	Empyema 01/2017
1	Cross Infection (Nosocomial Infection) 11/2016
1	Cardiomyopathies (Cardiomyopathy) 08/2013
1	Ototoxicity 09/2009

Drug/Important Bio-Agent (IBA)

14	Ceftaroline FDA Link 01/2021 - 11/2010
12	oritavancinIBA 01/2022 - 04/2012
10	Linezolid (Zyvox)FDA Link 01/2022 - 06/2008
10	dalbavancinIBA 06/2021 - 05/2015
8	telavancin FDA Link 01/2020 - 08/2010
7	ceftazidime drug combination avibactamIBA 12/2021 - 07/2015
6	Cephalosporins (Cephalosporin Antibiotics)IBA 07/2022 - 09/2012
5	ceftobiproleIBA 07/2022 - 01/2016
5	Carbapenems (Carbapenem Antibiotics)IBA 03/2022 - 04/2009
5	tedizolidIBA 06/2021 - 01/2019
4	avibactamIBA 03/2022 - 09/2012
4	Tazobactam FDA LinkGeneric 03/2022 - 06/2013
4	tazobactam drug combination ceftolozaneIBA 12/2021 - 09/2013
4	Anti-Bacterial Agents (Antibiotics)IBA 01/2019 - 07/2016
4	Vancomycin FDA LinkGeneric 11/2012 - 02/2010
3	Aztreonam FDA LinkGeneric 03/2022 - 10/2021
3	Pharmaceutical PreparationsIBA 01/2022 - 09/2013
3	CoagulaseIBA 07/2019 - 12/2009
2	Daptomycin FDA Link 01/2022 - 01/2020
2	ceftobiprole medocarilIBA 01/2020 - 07/2019
2	ProdrugsIBA 01/2020 - 07/2019
2	plazomicinIBA 05/2019 - 01/2018
2	LactamsIBA 01/2017 - 12/2015
2	beta-Lactamases (beta-Lactamase)IBA 04/2014 - 09/2008
2	ceftolozaneIBA 12/2013 - 06/2013
2	Tigecycline (Tygacil)FDA Link 04/2012 - 04/2008
1	Cefepime (Maxipime)FDA LinkGeneric 03/2022
1	Ceftibuten (Cedax)FDA Link 01/2022
1	Imipenem FDA Link 12/2021
1	relebactamIBA 12/2021
1	meropenem and vaborbactamIBA 12/2021
1	Sulfamethoxazole Drug Combination Trimethoprim (Co-Trimoxazole)FDA LinkGeneric 12/2020
1	Sulfamethoxazole FDA LinkGeneric 12/2020
1	Trimethoprim (Proloprim)FDA LinkGeneric 12/2020
1	FluoroquinolonesIBA 12/2020
1	SPR741IBA 04/2020
1	Ceftazidime (Fortum)FDA LinkGeneric 01/2019
1	tebipenemIBA 01/2019
1	Doripenem FDA Link 08/2018
1	Metronidazole (Metric)FDA LinkGeneric 01/2017
1	carbapenemaseIBA 01/2017
1	Meropenem (Merrem)FDA LinkGeneric 01/2017
1	MacrolidesIBA 01/2017
1	Piperacillin FDA LinkGeneric 04/2016
1	lefamulinIBA 01/2016
1	LipoglycopeptidesIBA 01/2016
1	Anti-Infective Agents (Microbicides)IBA 12/2014
1	EnzymesIBA 09/2012
1	quinupristin-dalfopristin (Synercid)FDA Link 04/2012
1	AminoglycosidesIBA 04/2012
1	TeicoplaninIBA 09/2011
1	Methicillin (Metin)FDA Link 09/2011
1	Fusidic Acid (Fucithalmic)IBA 06/2011
1	Oxazolidinones (2 Oxazolidone)IBA 12/2010
1	Fluconazole (Zonal)FDA LinkGeneric 09/2009
1	Tobramycin (Nebcin)FDA LinkGeneric 09/2009
1	Serine (L-Serine)FDA Link 09/2008

Therapy/Procedure

4	Therapeutics 01/2019 - 09/2009
2	Mechanical Ventilators (Ventilator) 11/2016 - 11/2010
1	Lasers (Laser) 03/2016
1	Drug Therapy (Chemotherapy) 04/2014
1	Heart-Assist Devices 08/2013